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Migraine  has been defined  as a common  disabling  primary  headache  disorder.   Epidemiology  studies 
have provided with the undeniable evidence of genetic components as active players in the development 
of the disease under a polygenic model in which multiple risk alleles exert modest individual effects.  Our 
objective  was  to  test  the  contribution  of  a  polygenic  effect  to  migraine  risk  in  the  Norfolk  Island 
population  using a panel of SNPs reported  to be disease associated  in published  migraine  GWAS. We 
also  investigated  whether  individual  SNPs  were  associated  with  gene  expression  levels  measured  in 
whole-blood.  Polygenic  scores  were  calculated  in  a  total  of  285  related  individuals  (74  cases,  211 
controls) from the Norfolk Island using 51 SNPs previously reported to be associated with migraine in 
published GWAS.   The association between polygenic score and migraine case-control status was tested 
using  logistic  regression.  Results  indicate  that  a  migraine  polygenic  risk  score  was  associated  with 
migraine case-control status in this population (P=0.016). This supports the hypothesis that multiple SNPs 
with weak effects collectively contribute to migraine risk in this population.  Amongst the SNPs included 
in the polygenic model, 4 were associated with the expression of the USMG5	gene, including rs171251 (P 
= 0.012).   Results from this study provide evidence for a polygenic contribution  to migraine risk in an  
isolated population and highlight specific SNPs that regulate the expression of USMG5, a gene critical for 
mitochondrial function. 
     





Migraine is a common disabling primary headache disorder, classified into two major groups, migraine 
without aura (MO) and migraine with aura (MA) (Levin	 2013).  MO is the most common form with 
headache attacks lasting between 4-72 hours.  In addition, MA sufferers often experience aural symptoms 
preceding the headache phase of the migraine episode. 
  
 
Although the pathophysiology of migraine is not very well understood, epidemiological studies have 
convincingly   demonstrated   that  genetic  components   contribute  to  the  development   of  the  disease. 
Genetic  risk  variants  have  been  identified  in  studies  of    Familial  Hemiplegic  Migraine  (FMH),  a 
monogenic form of MA; specifically, risk variants in/near CACNA1A, ATP1A2	 and SCNA1A	 (Ophoff,	
Terwindt	 et	 al.	 1996,	 Ambrosini,	 D'Onofrio	 et	 al.	 2005,	 Dichgans,	 Freilinger	 et	 al.	 2005). 
Additional  common  risk  variants  have  been  identified  through  Genome-Wide   Association   Studies 
(GWAS),  namely  rs9908234  (Ligthart,		de	 Vries	 et	 al.	 2011)		in NGFR, rs1835740  (Ligthart,		de	
Vries	 et	 al.	 2011,	 Anttila,	 Winsvold	 et	 al.	 2013)	 near PGCP, rs2651899 (PRDM16), rs10166942 
(TRPM8) and rs11172113 (LRP1) (Chasman,	 Schurks	 et	al.	2011). However, the replication of these 
variants in other populations has been challenging (Silberstein	 and	 Dodick	 2013), as has been the 
identification of new migraine risk variants. 
   
Genetic  studies  of  isolated  populations,  such  as  that  of  Norfolk  Island,  provide  improved  power  to 
identify genetic risk variants (Jorde,	Watkins	 et	al.	2000). Despite this, genetic studies of migraine in 
the Norfolk Island have failed to identify risk variants with large effects on disease risk (Cox,	Lea	et	al.	
2012,	Maher,	Lea	et	al.	2012,	Rodriguez‐‐‐Acevedo,	Maher	et	al.	2013). This suggests that in this 
 
isolated  population,  the  genetic  contribution  to  migraine  risk  might  be  mostly  determined  by  the 
combined effect of many risk variants with small effects. The aim of this study was to test this possibility 
by  estimating  a  migraine  polygenic  risk  score  for  individuals  in  the  Norfolk  Island  based  on  SNPs 






Norfolk  Island  belongs  to  the  Commonwealth  of  Australia  and  it  is  located  off  the  eastern  coast, 
approximately 1700 km northeast of Sydney, on the Norfolk Ridge. The modern Norfolk Island (NI) 
population  comes  from  a  settlement  of  194  inhabitants  resettled  from  Pitcairn  Island  in  1856  all 
descendants of nine male “Bounty” mutineers and twelve Tahitian women (Bellis, Cox et al. 2008). Since 
that time, the island has been isolated and strict immigration and quarantine legislation restricts migration 
to Norfolk.   Thus,  of the approximately  1200  current  permanent  residents,  up to 80%  can trace their 
heritage  back to the Island’s  initial  founders.  The heritability  of migraine  in this population  has been 
estimated to be 0.53 (Cox, Lea et al. 2012). 
  
Phenotypic  data and biological specimens (venous blood) were obtained from 600 subjects (261 males,  
339 females).   DNA was isolated using a standard salting-out procedure (Miller, Dykes et al. 1988). 
Phenotypic  data  was  obtained  via  a  medical  questionnaire   that  surveyed  migraine  family  history, 
symptoms, triggers, and medication use.  An in depth interview and comprehensive medical questionnaire 
was undertaken on all individuals and used to obtain phenotypic data, including migraine information 
regarding family history, symptoms, triggers and medication. Migraine diagnosis was in accordance with 
ICHD-II guidelines. The inclusion criteria used to select cases was a diagnostic of MA or MO with other 
non-migraineurs  included  in  the  control  population.    Genealogical  data  were  obtained  from  multiple 
sources,  including  questionnaire,  municipal  and historical  records.  Because  all the individuals  share  a 
common  genetic  background  and  under  the  hypothesis  of  a  common  major  variant,  all  individuals 
diagnosed  with  subtypes  MA  or  MO  were  grouped  together  and  phenotyped  as  being  affected  with 
migraine. The study protocol was initially approved by the Griffith University Human Research Ethics 
Committee and subsequently by the Queensland University of Technology Human Research Ethics 
Committee. All subjects provided signed, informed consent prior to participation. 
  
Genome-wide SNP genotyping  
DNA samples from the Norfolk Island Population were genotyped according to the manufacturer’s 
instructions  on  the  Illumina  Infinium  High  Density  (HD)  Human610-Quad  DNA  analysis  BeadChip 
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version  1. A total  of 620,901  genome  wide  markers  were  genotyped  in a sub-sample  of 285  related 
individuals (74 cases: 22 males and 52 females; and 211 controls: 114 males and 97 females). Twenty- 
eight selected samples (5% of both cases and controls) were repeated to ensure concordance and accuracy 
of genotyping. Samples were scanned on the Illumina BeadArray 500GX Reader. Raw data was obtained 
using Illumina BeadScan image data acquisition software (Version 2.3.0.13). 
  
SNPs selection and score calculation  
We used the Gene Central Database (Beck,	Hastings	 et	al.	2014)	 to select genetic variants previously 
associated  with  migraine  in published  GWAS.  Using  genotype  data  from  Europeans  of the  HapMap 
project  (International		 HapMap,		 Altshuler		 et		 al.		 2010),  we  reduced  this  list  of  SNPs  to  an 
independent set (r2<0.1) of 51 variants using PLINK (Purcell,	Neale	et	al.	2007)	(Supplemental Table 
1). Of note, each of these SNPs had previously been individually tested for association with migraine risk  




These  51 SNPs were used to calculate  a migraine  polygenic  score in PLINK  (Purcell,		Neale	 et	 al.	
 
2007).  The weight attributed to each SNP corresponded to the beta coefficient (β) reported in previous 
studies (Supplemental Table 1). Initially, the covariates age, sex and kinship were individually tested for 
association with migraine and only the significantly (P-value < 0.05) associated covariates were included 
in the final logistic regression model where the multiple allele score was set as a predictable variable and 
the migraine  phenotype  was set as the independent  variable.  In secondary  analyses,  the polygenic  risk 
score was also dichotomised to compare the risk of disease between the bottom and top 25% percentiles 
of the polygenic risk score distribution (Figure 1). 
  
Genome-wide expression  
Sample collection has been previously described (Benton, Lea et al. 2013). Expression profiling was 
performed with the HumanHT-12 v.4 Expression BeadChip Kit (Illumina) for a total number of 335 
individuals (79 cases and 256 controls).  Array images were scanned on the Illumina iScan and analyzed 
initially with the Gene Expression Module from GenomeStudio  (v.2011.1). Background subtraction was 
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applied,  and  missing  bead  types  were  imputed  with  GenomeStudio.  On  the  basis  of  the  number  of 
expressed  probes  (at  “detection  P  values”  ≤  0.05),  mean  raw  expression  values  across  probes,  and 
correlations  between  samples, all samples, with the exception  of one, provided  high-quality  data.   The 
sample with low-quality  data was removed.   Significantly  expressed  probes were then determined  at a 
false-discovery  rate  of  5%.    Subsequently,  the  raw  expression  levels  of  probes  detecting  significant 
expression were shifted by a constant amount so that the minimum observed value of any probe in any 




A total of 279 samples (72 cases and 207 controls) with both genotypic and levels of gene expression data 
were included in the analysis.  Transcripts within 1Mb of distance from each of the 51 SNPs included in 
the polygenic  model were selected  for analysis  using the University  of California  Santa Cruz (UCSC) 
table browser data retrieval web tool (Karolchik, Hinrichs et al. 2004).  We used linear regression to test 
the association between individual SNPs (coded additively) and gene transcription levels of genes located 
within 1Mb of each SNP. Genotypes were coded as 0, 1 or 2 according to the copies of a reference allele. 
In this study, the reference allele was the allele with the minor allele frequency (MAF). Gene-dropping 
simulations  under  the  null  hypothesis  of  no  association  were  used  to  correct  for  multiple  testing. 
Specifically, empirical P-values were obtained for each SNP after correcting the observed asymptotic P- 
value for the number of genes tested for that SNP (“locus-wide”  correction)  and for all the SNPs and 
genes tested in the analysis (a total of 418 tests; “study-wide” correction). Briefly, for each simulation, we 
(1) used Merlin (Abecasis,	Cherny	et	al.	2002)	 to generate random genotypes for the 51 SNPs for the 
279 related individuals; (2) tested each simulated SNP for association with the observed expression levels  
of the nearby genes, as in the real dataset; and (3) retained the most significant  P-value for each SNP 
across  all genes  tested  (for  “locus-wide”  correction)  and  the most  significant  P-value  across  all tests 
performed  (for  “study-wide”  correction).  This  procedure  was  repeated  1000  times,  and  the  retained 






We identified 140 SNPs previously reported to be associated with migraine in published GWAS, 
including a set of 51 SNPs in low linkage disequilibrium (r2<0.1) with each other (Supplemental Table 
1). Individually, all 51 SNPs were not significantly associated with the risk of migraine in the Norfolk 
Island population (Cox,	Lea	et	al.	2012). We reasoned that if some of these were indeed true risk 
factors with small effects on migraine susceptibility, then a polygenic risk score that aggregated the 
effects of all 51 SNPs would be significantly associated with disease status. To test this possibility, we 
used the association beta coefficient values reported by published migraine GWAS (Supplemental data 1) 
to generate a polygenic risk score across all 51 SNPs per individual. We found that this polygenic score 
was significantly and positively associated with migraine case-control status (P=0.016); cases had a 
higher load of risk alleles when compared to controls (Figure 1). Individuals in the top 25% of the 
polygenic score distribution were 3.1-fold (CI=1.37-7.55, P=0.008) more likely to be affected by 
migraine than individuals in the bottom 25% of the distribution (Figures 2 and 3). 
  
Fig.1 Scores vs Migraine boxplot distribution.  This figure shows the boxplot distribution of the scores in 
the controls and the cases in the Norfolk Island Population.   A significant P-value (0.016) was obtained 
after testing migraine and score correlation using a logistic regression model 
  
Fig.2 Histogram of Scores. Scores were calculated for all individuals in the population.  Individuals with 
extreme  scores    are  indicated  by  grey  (scores  ≤  0.003)  and  black  (scores  ≥  0.02)  bars.    A  logistic 
regression  analysis  showed  that  higher  scores  are  more  frequently  present  in  migraine  cases  than  in 
healthy controls (P-value = 0.008 ; OR = 3.11; CI=1.37-7.55) 
  
Fig.3 Bar plot for the score frequencies.   The frequency  of higher scores (≥0.02) (black), lower scores 
(≤0.003) (grey) and intermediate scores (0.02≥ scores ≤ 0.003) (white) among cases and controls shows a 
statistically significant   difference (χ2 = 6.81; P-value=0.0009; OR=2.94; CI= 1.28 to 6.73) in their 
distribution, which suggests that migraine sufferers tend to have a higher genetic load of risk alleles than 




In order  to evaluate  the potential  biological  role  played  by these  51 SNPs,  we tested  the association 
between each SNP and the expression levels of nearby genes. A total of 1347 genes were located within 
1Mb of one of the 51 SNPs. However, expression levels for only 327 of these genes were available in the 
Illumina array used, being represented by 337 probes. Results showed that 10 SNPs were significantly 
associated  with the expression  of a nearby gene after a locus-wide  correction  for the number of genes 
tested for each SNP (Table 1). Of these, the association  for 4 SNPs remained significant  after a study- 
wide correction for multiple testing (Figure 4): rs1712517 with USMG5 (corrected P=0.012); rs11172113 
with STAT6 (P=0.033); rs11906854 with CPNE1	 (P=0.044); and rs4803455 with BCKDHA (P=0.044). 
The predicted  biological  functions  for these genes are listed in Table 2. For USMG5  and STAT6,  the 
allele that increased  migraine  risk was associated  with increased  gene expression,  whereas  the reverse 
was observed for CPNE1	 and BCKDHA	 (Figure 3). We additionally  tested the correlation  between the 
levels of transcription of these eQTL genes and migraine status and no significant p-value (p≤0.05) was 
detected. 
  
Fig.4 Genotype vs Levels of expression Boxplot Distribution.  a. rs1712517 vs USMG5;b. rs11172113 vs 
STAT6;c. rs11906854 vs CPNE1; d. rs4803455 vs  BCKDHA. Significant eQTLs (S_P-value ≤ 0.05) are 
presented.     The  linearity  in  the  distribution   suggest  a  genetic  additive  model  followed  by  SNPs 
rs1712517, rs11172113, rs11906854 and rs4803455 influencing the levels of expression of the USMG5, 




As with other complex diseases, published GWAS confirm that common risk variants which individually 
explain a large proportion of migraine heritability do not exist. Instead, multiple risk variants with small 
and cumulative effects on the phenotype are most likely to explain the heritability of migraine. 
   
Consistent with this hypothesis, we found that a polygenic risk score computed based on SNPs identified 
in  published  GWAS  was  associated  with  migraine  case-control  status  in  the  isolated  population  of 
Norfolk  Island.  Our  results  also  support  a  regulatory   role  for  these  SNPs  on  the  expression   of 
mitochondrial,  immunological  and  hormonal  genes.  As  the  number  of  bona  fide  migraine  risk  SNPs 
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increases, a polygenic score can potentially be used to predict the risk of migraine and eventually it could 
represent  a predictor  with  better  discrimination  properties  between  different  sub-classifications  of the 
disorder.   This   methodology,   fitting   associated   and   non-associated   SNPs   simultaneously   into   the 
polygenic  model,  have  been  applied  successfully  in  the  past  to  explain  a  large  proportion  of  the 
heritability for human height (Yang,	 Benyamin	 et	 al.	 2010), schizophrenia and bipolar disorder 
(International	 Schizophrenia,	 Purcell	 et	 al.	 2009).  Similarly, more simplistic models where only 
associated variants from independent case-controls association studies are included were able to predict 
coronary heart disease (Morrison,	 Bare	et	al.	2007), and prostate cancer risk  (Aly,	Wiklund	 et	al.	
2011). This is the first time than the later methodology has been applied to support a polygenic model in 
migraine. 
   
The  score  analysis  provides  evidence  for  the  existence  of  a  polygenic  influence  on  susceptibility  of 
migraine; however, it provides little guidance as to which of the SNPs included in the polygenic score 
represent true migraine risk factors in the Norfolk Island population.  Results from our gene expression 
analysis  identified  4  SNPs  that  regulate  the  expression  of  a  nearby  gene,  which  provides  further 
independent support for these variants. The most significant association was observed between rs1712517 
and USMG5	 (Up-regulated during skeletal muscle growth) expression, which is consistent with results 
reported in a previous large GWAS of gene expression (Westra,	 Peters	 et	 al.	 2013).  Earlier studies 
in lymphoblastoid  cell lines (Stranger,	 Nica	 et	 al.	 2007,	 Veyrieras,	 Kudaravalli	 et	 al.	 2008)	 and 
in circulating monocytes (Zeller,	Wild	 et	al.	2010)	 also identified rs1712517 as an eQTL SNP for the 
USMG5		gene.  Interestingly,  the  USMG5		gene  is  highly  expressed  in  mitochondria  where  it  plays  a 
critical role in maintaining the ATP synthase population (Safran,	 Dalah	 et	 al.	 2010). Mitochondrial 
dysfunction can occur as a result of the reduce capacity to produce ATP, and this impairment in energy 
supply can affect the function of neurons and other cells, increasing the risk for neurological disorders 
(Alvarez,	 Corao	 et	 al.	 2008). USMG5	 also lies in a genomic region previously associated with 
schizophrenia  (Ripke,		O'Dushlaine		et		al.		2013).    In  our  study,  the  allele  that  increased  USMG5 
expression (G) was associated with decreased migraine risk. 
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Another notable association  was observed between rs11172113  and the expression of the STAT6	 gene, 
also consistent with previous reports (Stranger,	 Nica	et	al.	2007,	Westra,	 Peters	 et	al.	2013).  The 
protein encoded by the STAT6	 (Signal Transducer and Activator of Transcription 6) gene is a member of 
the  STAT  family  of  transcription  factors  which  carries  out  a  dual  function:  signal  transduction  and 
activation of transcription. It is also involved in IL4 (interleukin-4) and IL3 (interleukin-3) mediated 
signalling.  Cytokines are involved in a number of cellular processes including apoptosis, chemotaxis and 
cell proliferation and they have been associated with neuronal damage and pain in response to particular 
cellular  states,  such  as  hypothermia  and  hypoxia.    The  role  of  cytokines  in  the  neuro-inflammatory 




On the other hand, we discovered  a previously  unrecognised  eQTL for the BCKDHA	 gene, rs4803455, 
which is located 65Kb upstream of the transcription  start site. The allele that increased gene expression 
levels (A allele, Figure 4) was associated with increased migraine risk (Sumplemental Table 1).  BCKD is 
a mitochondrial multienzyme complex comprised of three catalytic components, one of them, a branched 
chain α-ketoacid decarboxylase  subunit (E1) is encoded by  the BCKDHA	 gene (D.T.	 Chuang	 2001). 
The gene is involved in the metabolism  of the essential branched-chain  amino acids (BCAAs) leucine, 
valine, and isoleucine and other mutations have been implicated in the development of maple syrup urine 
disease, an autosomal recessive metabolic disorder  (Wang,	Qi	et	al.	2012). 
 
 
Finally, the biggest limitation faced by this and other neurological studies (Borovecki,	 Lovrecic	 et	al.	
 
2005,	Vawter,	 Atz	 et	al.	2006,	 Seifuddin,	 Pirooznia	 et	al.	2013)	 is the use of expression profiles 
from peripheral  blood samples.   The reasons behind this fact are the inconsistency  of gene expression 
levels all through the brain caused by the  vast amount of cell types (Khaitovich, Muetzel et al. 2004) and 
the technical inconvenience in collecting brain tissue samples in post-mortem (Liu 2011).  This contrasts 
with the accessibility of peripheral blood tissue what in turn, facilitates the acquisition of a bigger sample 
size. Interestingly,  a recent  study  by McKenzie  et al. (McKenzie,  Henders  et al. 2014),  described  the 
eQTLs overlapping   in brain regions and blood, supporting the use of blood samples when conditions do 
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not allow the targeting of specific disease tissues. However, cell types specific to the pathophysiology  of 
the investigated disorder should be used whenever possible to perform transcription analysis.  
  
 
In conclusion, we provide evidence for a significant polygenic component to migraine risk in the isolated 
population of the Norfolk Island. Our results also point to two putative migraine risk genes that affect 







Results from this study provide evidence for  the existence of a polygenic influence in migraine driven by 
gene variants affecting mitochondrial, immunological and hormonal gene mRNA levels in the cellular 
environmental.    Additionally,  we have  replicated  eQTLs  from  previous  studies  further  validating  our 
approach.  We have also reported four eQTLs (rs1712517-USMG5; rs11172113-STAT6; rs11906854- 
CPNE1;  rs4803455-  BCKDHA)  interacting  with  genes  relevant  to  the  migraine  pathophysiology  that 
were significant at a study level.  The rs4803455-BCKDHA		is a novel eQTL reported for the first time in 
this study. Further studies are needed to fully understand the role of these variants in the development of 
migraine.    Thus,  this  study  open  doors  to  the  investigation  of  novel  biological  targets  for  migraine 
treatment to be considered in future studies. 
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rs1712517   G   0.4462   ILMN_1773313   USMG5   0.00003   <0.001   0.012   0.83   0.76‐‐‐0.90   T  
rs11172113   C   0.4104   ILMN_1763198   STAT6   0.00008   0.001   0.033   0.87   0.81‐‐‐0.93   T  
rs11906854   G   0.1147   ILMN_2276000   CPNE1   0.0001   <0.001   0.044   0.82   0.71‐‐‐0.89   G  
rs4803455   A   0.4588   IILMN_1670841   BCKDHA   0.0001   0.003   0.044   0.8   0.71‐‐‐0.89   C  
rs11906854   G   0.1147   ILMN_1670841   CPNE1   0.0004   0.004   0.16   0.79   0.70‐‐‐0.90   G  
rs3094117   G   0.3297   ILMN_1721113   HLA‐‐‐C   0.0004   0.016   0.16   1.46   1.18‐‐‐1.80   T  
rs7085387   G   0.233   ILMN_1715661   TFAM   0.0006   0.004   0.26   1.17   1.07‐‐‐1.28   A  
rs2076054   C   0.276   ILMN_1715963   FBXO7   0.001   0.014   0.44   1.25   1.08‐‐‐1.45   C  
rs3094117   G   0.3297   ILMN_1716922   DHX16   0.002   0.082   0.82   0.93   0.86‐‐‐0.97   T  
rs3094117   G   0.3297   ILMN_2101885   TUBB   0.002   0.082   0.82   0.91   0.86‐‐‐0.97   T  
rs10037055   T   0.2572   ILMN_2278850   RAB24   0.002   0.082   0.82   0.93   0.89‐‐‐0.97   G  
rs10037055   T   0.2572   ILMN_1714393   RAB24   0.003   <0.001   1.23   1.08   1.02‐‐‐1.14   G  
rs11906854   G   0.1147   ILMN_1795317   SCAND1   0.003   0.047   1.23   1.17   1.05‐‐‐1.30   G  
rs2274316   C   0.3065   ILMN_2126239   SMG5   0.009   0.366   3.67   1.07   1.01‐‐‐1.13   C  
rs11906854   G   0.1147   ILMN_2411963   RBM39   0.013   0.21   5.51   1.12   1.02‐‐‐1.22   G  
rs2274316   C   0.3065   ILMN_1696749   LMNA   0.024   0.94   11.76   1.09   1.01‐‐‐1.17   C  
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rs10037055  RAB24   RAS oncogene family    Involved in autophagy related processes  
rs11906854  SCAND1   SCAN Domain Containing 1   May regulate transcriptional activity  
rs2274316   SMG5   SMG5 Nonsense Mediated   mRNA decay factor  
rs11906854  RBM39   RNA Binding Motif Proteins   Transcriptional coactivator for steroid nuclear receptors esr1 er‐‐‐alpha and esr2.  
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Supplementary Table 1. Fifty-one SNPs were included in the multi-marker scoring analysis.  Here, we show the general information provided for every SNP 
from previous GWASs. From left to right, the columns show the SNP name, chromosomal region, chromosomal position, the associated trait (MO: Migraine 
without Aura; MA: Migraine with Aura), Associated Allele (Assoc Alle),  Risk Allele Frequency (RAF), P-value, Odd Ratio (OR), 95% Confidence Interval 
(95%CI), Study were the SNP was reported and the platform used to perform the SNP array. 
 
SNP   Region   Chr. Position   Trait   Assoc Alle  RAF   P‐‐‐val   OR   95% CI   Study   Platform  
rs10037055   5q35.3   177264278   Migraine MO  G   0.83   5.00E‐‐‐06  1.14   [1.08‐‐‐1.19]  Anttila V   Affmetrix & Illumina [~2.3 million]     
rs10166942   2q37.1   233916448   Migraine   T   0.82   1.00E‐‐‐12  1.28   [1.19‐‐‐1.37]  Freilinger T  Illumina [1,246,388]     
rs10820447   9q22.32   96369762   Migraine MA  T   0.16   6.00E‐‐‐06  1.16   [1.09‐‐‐1.23]  Anttila V   Affmetrix & Illumina [~2.3 million]     
rs10826566   10p12.1   29075768   Migraine MA  A   0.17   4.00E‐‐‐06  1.16   [1.09‐‐‐1.23]  Anttila V   Affmetrix & Illumina [~2.3 million]     
rs10997517   10q21.3   67120045   Migraine MO  C   0.23   6.00E‐‐‐06  1.14   [1.08‐‐‐1.21]  Anttila V   Affmetrix & Illumina [~2.3 million]     
rs11172113   12q13.3   57133500   Migraine   T   0.57   4.00E‐‐‐19  1.11   [1.09‐‐‐1.14]  Anttila V   Affmetrix & Illumina [~2.3 million]     
rs11594111   10p13   14903407   Migraine   G   0.14   1.00E‐‐‐07  1.09   [1.06‐‐‐1.12]  Anttila V   Affmetrix & Illumina [~2.3 million]     
rs11636768   15q25.3   87152280   Migraine   A   0.15   5.00E‐‐‐07  1.25   [NR]   Ligthart L   Affymetrix, Illumina & Perlegen [~2.5 m]   
   
SNP  Region  Chr. Position  Trait  Assoc Alle  RAF  P‐‐‐val  OR  95% CI  Study  Platform 
rs11726563  4p12  46821617  Migraine  A  0.84  8.00E‐‐‐06  1.16  [1.09‐‐‐1.23]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs11777116  8p21.2  24186788  Migraine  T  0.08  6.00E‐‐‐08  1.27  [1.17‐‐‐1.39]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs11906854  20q11.22  35795712  Migraine  G  0.14  7.00E‐‐‐06  1.17  [1.09‐‐‐1.26]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs12282928  11p11.2  48310476  Migraine  A  0.77  9.00E‐‐‐06  1.14  [1.08‐‐‐1.2]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs12365397  11p12  43214511  Migraine  A  0.68  9.00E‐‐‐06  1.05  [1.03‐‐‐1.09]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs12454023  18q21.31  58342372  Migraine MA  T  0.5  8.00E‐‐‐07  1.12  [1.08‐‐‐1.18]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs13263568  8q13.3  71535183  Migraine  G  0.09  2.00E‐‐‐06  1.1  [1.06‐‐‐1.14]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs1364402  7q33  136899616  Migraine MA  T  0.91  4.00E‐‐‐06  1.19  [1.11‐‐‐1.28]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs140174  22q11.23  23580796  Migraine  G  0.26  8.00E‐‐‐06  1.08  [NR]  Ligthart L  Affymetrix,  Illumina & Perlegen  [~2.5 m] 
rs1485395  12q13.13  53601293  Migraine MO  C  0.16  7.00E‐‐‐06  1.13  [1.07‐‐‐1.19]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs1712517  10q24.33  103273258  Migraine  T  0.48  9.00E‐‐‐06  1.13  [1.07‐‐‐1.17]  Freilinger T  Illumina  [1,246,388] 
rs17301853  1q25.1  174583673  Migraine MO  C  0.88  7.00E‐‐‐06  1.19  [1.1‐‐‐1.28]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs1835740  8q22.1  97154685  Migraine  A  0.21  2.00E‐‐‐11  1.18  [1.13‐‐‐1.24]  Anttila V  Illumina  [429,912] 
rs1861960  7q36.3  155492440  Migraine  T  0.2  6.00E‐‐‐06  1.07  [1.04‐‐‐1.10]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs2076054  22q12.3  32436887  Migraine MA  C  0.26  8.00E‐‐‐06  1.12  [1.07‐‐‐1.18]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs2274316  1q22  156476450  Migraine  C  0.36  1.00E‐‐‐08  1.07  [1.05‐‐‐1.10]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs2506155  10p11.22  33214251  Migraine  A  0.15  3.00E‐‐‐06  1.08  [1.04‐‐‐1.11]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs2651899  1p36.32  3167148  Migraine  C  0.41  4.00E‐‐‐14  1.09  [1.07‐‐‐1.11]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs2723279  12q24.23  117835066  Migraine  G  0.69  5.00E‐‐‐06  1.06  [1.03‐‐‐1.09]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs2877098  7p14.1  41703696  Migraine MO  C  0.66  2.00E‐‐‐06  1.11  [1.06‐‐‐1.16]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs2946505  8p22  12953643  Migraine  A  0.78  9.00E‐‐‐06  1.06  [1.03‐‐‐1.09]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs3094117  6p21.33  30769709  Migraine MO  T  0.77  2.00E‐‐‐06  1.12  [1.06‐‐‐1.18]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs378363  9p23  9020223  Migraine  A  0.77  8.00E‐‐‐06  1.14  [1.08‐‐‐1.2]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs400824  8q21.13  80445467  Migraine  A  0.7  9.00E‐‐‐06  1.12  [1.06‐‐‐1.19]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs4379368  7p14.1  40426601  Migraine MO  T  0.11  1.00E‐‐‐09  1.11  [1.08‐‐‐1.15]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs4478147  4q21.3  86552623  Migraine  G  0.47  2.00E‐‐‐06  1.12  [1.07‐‐‐1.18]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs4493873  8q21.3  91063415  Migraine  C  0.64  5.00E‐‐‐06  1.14  [1.08‐‐‐1.2]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs4803455  19q13.2  41345604  Migraine  C  0.5  8.00E‐‐‐07  1.05  [1.03‐‐‐1.08]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
   
SNP  Region  Chr. Position  Trait  Assoc Alle  RAF  P‐‐‐val  OR  95% CI  Study  Platform 
rs4880487  10p15.3  1200943  Migraine  T  0.25  3.00E‐‐‐06  1.06  [1.04‐‐‐1.09]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs4909945  11p15.4  10652192  Migraine  C  0.67  2.00E‐‐‐07  1.06  [1.04‐‐‐1.09]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs516243  1p36.22  10690375  Migraine  A  0.49  9.00E‐‐‐06  1.11  [1.06‐‐‐1.17]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs543844  6p21.1  44457063  Migraine  G  0.34  3.00E‐‐‐06  1.06  [1.03‐‐‐1.08]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs6478241  9q33.1  116490350  Migraine  A  0.38  1.00E‐‐‐09  1.16  [1.11‐‐‐1.22]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs6479874  10q11.23  51029595  Migraine  T  0.14  3.00E‐‐‐07  1.09  [1.05‐‐‐1.12]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs6583954  10q23.33  94774506  Migraine  T  0.14  4.00E‐‐‐06  1.08  [1.04‐‐‐1.11]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs6756590  2q35  216343848  Migraine  T  0.56  1.00E‐‐‐06  1.14  [1.08‐‐‐1.2]  Freilinger T  Illumina  [1,246,388] 
rs6790925  3p24.1  30438593  Migraine  T  0.38  2.00E‐‐‐08  1.15  [1.10‐‐‐1.21]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs705162  10q26.13  123492159  Migraine  A  0.26  3.00E‐‐‐06  1.06  [1.04‐‐‐1.09]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs7068341  10p13  16592300  Migraine  T  0.12  2.00E‐‐‐06  1.09  [1.05‐‐‐1.12]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs7085387  10q21.1  58444842  Migraine MO  A  0.8  2.00E‐‐‐06  1.14  [1.08‐‐‐1.19]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs7718446  5q32  146369972  Migraine MO  A  0.72  4.00E‐‐‐06  1.11  [1.06‐‐‐1.16]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
rs9349379  6p24.1  12903725  Migraine  A  0.6  5.00E‐‐‐08  1.08  [1.04‐‐‐1.1]  Anttila V  Affmetrix & Illumina  [~2.3 million] 
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